|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Capoluongo E, Ellison G, López-Guerrero
JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C,
Friedman E, Markiefka B, Schirmacher P, et al: Guidance statement
On BRCA1/2 tumor testing in ovarian cancer patients. Semin Oncol.
44:187–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vargas-Hernández VM, Moreno-Eutimio MA,
Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent
epithelial ovarian cancer. Gland Surg. 3:198–202. 2014.PubMed/NCBI
|
|
5
|
Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia
J and Xu D: CIP2A is overexpressed in gastric cancer and its
depletion leads to impaired clonogenicity, senescence, or
differentiation of tumor cells. Clin Cancer Res. 14:3722–3728.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khanna A, Böckelman C, Hemmes A, Junttila
MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C,
et al: MYC-dependent regulation and prognostic role of CIP2A in
gastric cancer. J Natl Cancer Inst. 101:793–805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Côme C, Laine A, Chanrion M, Edgren H,
Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al:
CIP2A is associated with human breast cancer aggressivity. Clin
Cancer Res. 15:5092–5100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi YA, Park JS, Park MY, Oh KS, Lee MS,
Lim JS, Kim KI, Kim KY, Kwon J, Yoon DY, et al: Increase in CIP2A
expression is associated with doxorubicin resistance. FEBS Lett.
585:755–760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yin X, Zhang N and Di W: Regulation of
LC3-dependent protective autophagy in ovarian cancer cells by
protein phosphatase 2A. Int J Gynecol Cancer. 23:630–641. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miller DS, Blessing JA, Krasner CN, Mannel
RS, Hanjani P, Pearl ML, Waggoner SE and Boardman CH: Phase II
evaluation of pemetrexed in the treatment of recurrent or
persistent platinum-resistant ovarian or primary peritoneal
carcinoma: A study of the gynecologic oncology group. J Clin Oncol.
27:2686–2691. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burger RA: A new model of ovarian
carcinogenesis may influence early detection strategies. Am J
Obstet Gynecol. 198:349–350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Wang M, Zhang X, Wang Q, Qi M, Hu
J, Zhou Z, Zhang C, Zhang W, Zhao W and Wang X: CIP2A is associated
with multidrug resistance in cervical adenocarcinoma by a
P-glycoprotein pathway. Tumour Biol. 37:2673–2682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen KF, Liu CY, Lin YC, Yu HC, Liu TH,
Hou DR, Chen PJ and Cheng AL: CIP2A mediates effects of bortezomib
on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Oncogene. 29:6257–6266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen KF, Pao KC, Su JC, Chou YC, Liu CY,
Chen HJ, Huang JW, Kim I and Shiau CW: Development of erlotinib
derivatives as CIP2A-ablating agents independent of EGFR activity.
Bioorg Med Chem. 20:6144–6153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tseng LM, Liu CY, Chang KC, Chu PY, Shiau
CW and Chen KF: CIP2A is a target of bortezomib in human triple
negative breast cancer cells. Breast Cancer Res. 14:R682012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW,
Cheng AL and Chen KF: Cancerous inhibitor of protein phosphatase 2A
mediates bortezomib-induced autophagy in hepatocellular carcinoma
independent of proteasome. PLoS One. 8:e557052012. View Article : Google Scholar
|
|
19
|
Chattopadhyay S, Machado-Pinilla R,
Manguan-Garcı'a C, Belda-Iniesta C, Moratilla C, Cejas P,
Fresno-Vara JA, de Castro-Carpeño J, Casado E, Nistal M, et al:
MKP1/CL100 controls tumor growth and sensitivity to cisplatin in
non-small-cell lung cancer. Oncogene. 25:3335–3345. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ,
Liu YQ, Pu JX, Xiao WL, Sun HD and Zhou GB: Overexpression and
small molecule-triggered downregulation of CIP2A in lung cancer.
PLoS One. 6:e201592011. View Article : Google Scholar : PubMed/NCBI
|
